

Seigo Nakamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/764694/publications.pdf>

Version: 2024-02-01

48
papers

995
citations

516215

16
h-index

476904

29
g-index

49
all docs

49
docs citations

49
times ranked

1707
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. <i>Nature Communications</i> , 2018, 9, 4083.	5.8	179
2	Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts. <i>Breast Cancer</i> , 2017, 24, 104-110.	1.3	106
3	Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. <i>Breast Cancer</i> , 2015, 22, 235-244.	1.3	58
4	Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. <i>Journal of Human Genetics</i> , 2018, 63, 447-457.	1.1	58
5	Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 163-172.	1.1	50
6	Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. <i>Cancer Medicine</i> , 2016, 5, 1328-1340.	1.3	42
7	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice in the EMBRACE study. <i>Breast Cancer</i> , 2020, 27, 706-715.	1.3	41
8	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 299-304.	1.1	39
9	Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 191-197.	1.1	38
10	The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. <i>Journal of Human Genetics</i> , 2021, 66, 307-314.	1.1	32
11	Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75% gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013). <i>Supportive Care in Cancer</i> , 2016, 24, 2583-2590.	1.0	29
12	The β -catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5. <i>Experimental Cell Research</i> , 2015, 338, 22-31.	1.2	27
13	Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2 ⁺ Early-stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 474-480.	1.1	21
14	Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. <i>Npj Breast Cancer</i> , 2020, 6, 25.	2.3	21
15	Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 485-494.	1.1	18
16	The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype. <i>Clinical Breast Cancer</i> , 2018, 18, e219-e229.	1.1	18
17	Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation <i>BRCA1</i> L63X. <i>Oncotarget</i> , 2019, 10, 3276-3284.	0.8	18
18	Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. <i>Investigational New Drugs</i> , 2017, 35, 791-799.	1.2	16

#	ARTICLE	IF	CITATIONS
19	Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2018, 25, 43-49.	1.3	16
20	Differences in perception of breast cancer treatment between patients, physicians, and nurses and unmet information needs in Japan. <i>Supportive Care in Cancer</i> , 2020, 28, 2331-2338.	1.0	15
21	Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1105-1110.	1.0	14
22	Magnetically Promoted Rapid Immunofluorescence Staining for Frozen Tissue Sections. <i>Journal of Histochemistry and Cytochemistry</i> , 2019, 67, 575-587.	1.3	11
23	Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. <i>Breast Cancer</i> , 2016, 23, 62-72.	1.3	10
24	Moving a neodymium magnet promotes the migration of a magnetic tracer and increases the monitoring counts on the skin surface of sentinel lymph nodes in breast cancer. <i>BMC Medical Imaging</i> , 2020, 20, 58.	1.4	10
25	How pregnancy and childbirth affect the working conditions and careers of women surgeons in Japan: findings of a nationwide survey conducted by the Japan Surgical Society. <i>Surgery Today</i> , 2021, 51, 309-321.	0.7	10
26	Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. <i>Antibodies</i> , 2021, 10, 6.	1.2	10
27	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, 6, e2000368.	1.5	9
28	Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 841-849.	1.1	8
29	Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges. <i>Pharmacogenomics</i> , 2020, 21, 359-367.	0.6	8
30	Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. <i>Breast Cancer</i> , 2020, 27, 85-91.	1.3	7
31	QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer. <i>The Journal of Breast Health</i> , 2018, 14, 194-198.	0.4	7
32	Differences in age at diagnosis of ovarian cancer for each <i>BRCA</i> mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	7
33	Diagnostic performance of dedicated breast positron emission tomography. <i>Breast Cancer</i> , 2022, 29, 1013-1021.	1.3	7
34	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 455-461.	1.1	6
35	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004. <i>Breast Cancer</i> , 2016, 23, 39-49.	1.3	5
36	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005. <i>Breast Cancer</i> , 2016, 23, 50-61.	1.3	5

#	ARTICLE	IF	CITATIONS
37	The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. <i>Breast Cancer</i> , 2020, 27, 586-593.	1.3	5
38	Diagnostic performance of coronal view in comparison with transverse view of three-dimensional automated breast ultrasound. <i>Acta Radiologica</i> , 2021, 62, 27-33.	0.5	3
39	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. <i>Cancer Science</i> , 2021, 112, 1310-1319.	1.7	3
40	Development of Support System for Breast Cancer Patients--Managing Side Effects through an Internet-Based System. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2016, 43, 85-90.	0.2	1
41	Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma. <i>Breast Cancer</i> , 2022, 29, 610-617.	1.3	1
42	Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy. <i>The Journal of Breast Health</i> , 2022, 18, 155-162.	0.4	1
43	For choosing axillary treatment, and adjuvant hormonal treatment. <i>Breast Cancer</i> , 2016, 23, 167-169.	1.3	0
44	Significance of Ki-67 Expression and Risk Category (St. Gallen 2007) in Elderly Breast Cancer Patients, with Emphasis on the Need for Postoperative Adjuvant Therapy. <i>The Showa University Journal of Medical Sciences</i> , 2011, 23, 153-164.	0.1	0
45	The negative prognostic impact of downstaging after neoadjuvant chemotherapy in patients with hormone-receptor positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11524-e11524.	0.8	0
46	Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy. , 2019, 2, 877-884.		0
47	Frequency of high-risk hormone receptor-positive breast cancer patients was much higher in Japanese breast cancer patients with germline <i>BRCA1/2</i> mutations than in sporadic breast cancer patients. <i>Breast Journal</i> , 2021, 27, 188-190.	0.4	0
48	Comparison between a new assay system, Elecsys® Anti-p53, and conventional MESACUPâ„¢ for the detection of serum anti-p53 antibodies: A multi-institutional study. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	0